 |
 5 Syringe Pens + 4 Syringe Highlighters $6.00 Time Remaining: 1d 11h 47m Buy It Now for only: $6.00 |
 4 Syringe Highlighter Assorted Colors $3.00 Time Remaining: 1d 11h 47m Buy It Now for only: $3.00 |
 15 Syringe Highlighters Blue $14.25 Time Remaining: 1d 11h 58m Buy It Now for only: $14.25 |
 15 PENS Syringe Highlighters Yellow plus a FREE GIFT $14.25 Time Remaining: 1d 11h 58m Buy It Now for only: $14.25 |
 15 Syringe Highlighters Green $14.25 Time Remaining: 1d 11h 58m Buy It Now for only: $14.25 |
 50 Syringe Highlighters Green $47.50 Time Remaining: 1d 11h 58m Buy It Now for only: $47.50 |
 50 Syringe Highlighters Blue $47.50 Time Remaining: 1d 11h 58m Buy It Now for only: $47.50 |
 50 Syringe Highlighter Pink $47.50 Time Remaining: 1d 11h 58m Buy It Now for only: $47.50 |
Syringe Highlighters
R&D Trends: Insulin Antidiabetics - The future is analogs - Market Analysis Report
Aarkstore.com announce a new report through its vast collection of market research report :
R&D Trends: Insulin Antidiabetics - The future is analogs
For some-more information, Great fully visit:
http://www.aarkstore.com/reports/R-D-Trends-Insulin-Antidiabetics-The-future-is-analogs-136238.html
Introduction
The insulin antidiabetic pipeline can be split between small manufacturers, often targeting reformulations of existing insulin, and major manufacturers pursuing novel insulin analogs. Pipeline products will need to show improvements in the clinical safety/side-effect profile of insulins, as change in delivery method alone will not be enough to gain market share.
Features and benefits
* Comprehensive analysis of the current insulin antidiabetic pipeline including both reformulations of marketed insulins and novel analog products.
* Establish the minimum acceptable and target product profiles necessary for success in the insulins market
* Assess future directions in insulin therapies in diabetes.
* Provide insight into clinical trial design and trends in insulin antidiabetics
Highlights
The insulin pipeline consists of 26 clinical trial candidates, of which 20 are in Phase I or Phase II development. Small manufacturers are developing reformulations of human insulin to improve delivery or pharmacological profile, while major insulin players are focusing entirely on analog insulins and combinations.
Comparator insulins Lantus, NovoRapid, and Novomix are well accepted in the market, but pipeline products can target unmet needs associated with clinical safety and side effects, particularly by reducing hypoglycemia and reducing weight gain.
A key future trend in insulin use is the growing utilization of technology: sophisticated pen injectors are replacing traditional vial and syringe delivery, and the use of insulin pumps to deliver a calibrated dose regime is growing.
Your key questions answered
* updated, comprehensive overview of the diabetes pipeline.
* Assess the remaining market opportunities and barriers to uptake for novel insulin therapies and formulations.
* Identify clinical trial requirements and trends in insulin antidiabetics.
Table of Contents :
Executive Summary
Strategic scoping and focus
key findings
Diabetes reports in the seven major markets
Growth markets diabetes reports
OVERVIEW
Catalyst
Summary
CLINICAL PIPELINE OVERVIEW
Insulin antidiabetics
Prandial insulins comprise more than half the pipeline
Key companies in insulins market: Novo Nordisk continues to build insulin analog franchise
Small manufacturers focus on reformulations of human insulin
Traditional injectable delivery is favored by developers
Development compounds recently discontinued
Linjeta (VIAject insulin; Biodel)
TARGET PRODUCT PROFILE
Comparator insulin therapies
Basal insulin comparator: Lantus (insulin glargine; Sanofi-Aventis)
Fast-acting insulin comparator: NovoRapid (insulin aspart; Novo Nordisk)
Premixed insulin comparator: Novomix (insulin aspart+insulin aspart protamine; Novo Nordisk)
Target product profile versus current level of attainment
Side effects of insulin treatment
Insulin delivery and dosing
CLINICAL TRIAL DESIGN IN INSULIN ANTIDIABETICS
About the Author
We specialize in providing online market business information on market research reports, books, magazines, conference booking at competitive prices, and strive to provide excellent and innovative service to our customers.